TY - JOUR
T1 - Influenza vaccination in Western Australian children
T2 - Exploring the health benefits and cost savings of increased vaccine coverage in children
AU - Blyth, Christopher C.
AU - Fathima, Parveen
AU - Pavlos, Rebecca
AU - Jacoby, Peter
AU - Pavy, Olivia
AU - Geelhoed, Elizabeth
AU - Richmond, Peter C.
AU - Effler, Paul V.
AU - Moore, Hannah C.
N1 - Funding Information:
The work was supported by a Research Translation Grant from WA Department of Health as well as support from Telethon Kids Institute and the Wesfarmers Centre of Vaccines and Infectious Diseases. During the period of the study: HCM was supported by a Stan Perron Charitable Foundation Fellowship and a Future Health Research and Innovation Fund through the WA Near-miss Awards program; CCB was supported by a NHMRC Career Development Fellowship and Investigator Grant.
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/12
Y1 - 2023/12
N2 - Introduction: To assess potential benefits and direct healthcare cost savings with expansion of an existing childhood influenza immunisation program, we developed a dynamic transmission model for the state of Western Australia, evaluating increasing coverage in children < 5 years and routinely immunising school-aged children. Methods: A deterministic compartmental Susceptible-Exposed-Infectious-Recovered age-stratified transmission model was developed and calibrated using laboratory-notification and hospitalisation data. Base case vaccine coverage estimates were derived from 2019 data and tested under moderate, low and high vaccine effectiveness settings. The impact of increased coverage on the burden of influenza, influenza-associated presentations and net costs were assessed using the transmission model and estimated health utilisation costs. Results: Under base case vaccine coverage and moderate vaccine effectiveness settings, 225,460 influenza cases are expected annually across all ages. Direct healthcare costs of influenza were estimated to be A$27,608,286 per annum, dominated by hospital costs. Net cost savings of >$A1.5 million dollars were observed for every 10 % increase in vaccine coverage in children < 5 years. Additional benefits were observed by including primary school age children (5–11 years) in the funded influenza vaccination program - a reduction in cases, presentations, hospitalisations and approximately $A4 million net costs savings were observed for every 10 % increase in coverage. The further addition of older children (12–17 years) resulted in only moderate additional net cost savings figures, compared with a 5–11year-old program alone. Net costs savings were predominantly derived by a reduction in influenza-associated hospitalisation in adults. Conclusions: Any increase in influenza vaccine coverage in children < 5 years, above a base case of 50 % coverage resulted in a substantive reduction in influenza cases, presentations, hospitalisations and net costs when applied to the West Australian population. However, the most impactful pediatric program, from both a disease prevention and costs perspective, would be one that increased vaccination coverage among primary-school aged children.
AB - Introduction: To assess potential benefits and direct healthcare cost savings with expansion of an existing childhood influenza immunisation program, we developed a dynamic transmission model for the state of Western Australia, evaluating increasing coverage in children < 5 years and routinely immunising school-aged children. Methods: A deterministic compartmental Susceptible-Exposed-Infectious-Recovered age-stratified transmission model was developed and calibrated using laboratory-notification and hospitalisation data. Base case vaccine coverage estimates were derived from 2019 data and tested under moderate, low and high vaccine effectiveness settings. The impact of increased coverage on the burden of influenza, influenza-associated presentations and net costs were assessed using the transmission model and estimated health utilisation costs. Results: Under base case vaccine coverage and moderate vaccine effectiveness settings, 225,460 influenza cases are expected annually across all ages. Direct healthcare costs of influenza were estimated to be A$27,608,286 per annum, dominated by hospital costs. Net cost savings of >$A1.5 million dollars were observed for every 10 % increase in vaccine coverage in children < 5 years. Additional benefits were observed by including primary school age children (5–11 years) in the funded influenza vaccination program - a reduction in cases, presentations, hospitalisations and approximately $A4 million net costs savings were observed for every 10 % increase in coverage. The further addition of older children (12–17 years) resulted in only moderate additional net cost savings figures, compared with a 5–11year-old program alone. Net costs savings were predominantly derived by a reduction in influenza-associated hospitalisation in adults. Conclusions: Any increase in influenza vaccine coverage in children < 5 years, above a base case of 50 % coverage resulted in a substantive reduction in influenza cases, presentations, hospitalisations and net costs when applied to the West Australian population. However, the most impactful pediatric program, from both a disease prevention and costs perspective, would be one that increased vaccination coverage among primary-school aged children.
KW - Child
KW - Costs
KW - Influenza
KW - Influenza vaccination
UR - http://www.scopus.com/inward/record.url?scp=85174826205&partnerID=8YFLogxK
U2 - 10.1016/j.jvacx.2023.100399
DO - 10.1016/j.jvacx.2023.100399
M3 - Article
C2 - 37908895
AN - SCOPUS:85174826205
SN - 2590-1362
VL - 15
JO - Vaccine: X
JF - Vaccine: X
M1 - 100399
ER -